Surmodics, Inc. (Nasdaq: SRDX), a leading provider of medical device and in vitro diagnostic technologies to the healthcare industry, today reported financial ...

Scholar Rock submitted its BLA of apitegromab for the treatment of patients with Spinal Muscular Atrophy with a request for Priority Review to be given. Explore more details here.

It was about a year ago that shares of Iovance Biotherapeutics (NASDAQ: IOVA) began to take off. Could this be a great buying ...

We run the ruler over ASX health stock quarterlies, with Bioxyne achieving record Q2 FY25 trading revenue. ... Read More The post ASX Quarterly Health Wrap: Bioxyne revenue up 77%, Radiopharm lists on ...

Several ASX-listed companies are undertaking phase III clinical trials, the critical final stage before potential regulatory ...

Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB), a commercial-stage biopharmaceutical company with a "GOOD" InvestingPro Financial ...

AstraZeneca PLC (LON:AZN), a leading global biopharmaceutical company with a market capitalization of $216.74 billion, has been making significant strides in the pharmaceutical industry, particularly ...

Solid Biosciences Inc. (NASDAQ:SLDB), a biotechnology company with a market capitalization of $133 million, recently reported that Ilan Ganot, a director at the company, engaged in stock transactions ...

Carlsbad-based Tyra Biosciences , Inc. announced a change in its Board of Directors, according to a recent SEC filing. On ...

CARLSBAD, Calif. - Tyra Biosciences , Inc. (NASDAQ:TYRA), a biotech firm specializing in precision medicines targeting Fibroblast Growth Factor Receptor (FGFR) biology, today announced the appointment ...

Jefferies analyst Akash Tewari adjusted the price target for Zentalis Pharmaceuticals (NASDAQ:ZNTL), bringing it down to $2.50 from the previous figure of $6.00, while reiterating a Hold rating on the ...

We recently published a list of 10 Unstoppable Stocks to Buy in 2025. In this article, we are going to take a look at where ...